Pharmaceuticals News and Research

RSS

Center for Technology and Aging announces grants to improve medication use in older adults

The Center for Technology and Aging today announced grants to five organizations for projects that promise to help improve medication use in older adults with chronic health conditions.

6 Jan 2010

U.S. market for urological devices to reach over $5.4 billion in 2016

According to a new global report series by iData Research, the leading authority in medical device, dental and pharmaceutical market research, the U.S. market for urological devices is estimated to more than double in value by 2016, reaching over $5.4 billion.

6 Jan 2010

Historic low in drug spending growth coincides with cost-saving tools developed by PBMs

Expenditures on prescription drugs increased just 3.2 percent in 2008 – the smallest annual rate of increase in 47 years – according to new data released today by the Centers for Medicare and Medicaid Services (CMS).

6 Jan 2010

Study reveals majority of drug companies utilize in-house call centers

Cutting Edge Information's most recent medical information study reveals that drug companies overwhelmingly agree that operating medical information call centers in-house is more efficient.

6 Jan 2010

Patient enrolled in Phase I clinical study of two investigational compounds: MK-2206 and AZD6244

Dr. Anthony Tolcher, clinical director for South Texas Accelerated Research Therapeutics (START) at the START Center for Cancer Care in San Antonio, announced today that the first patient has been enrolled in a groundbreaking Phase I clinical trial of a novel combination anticancer regimen composed of two investigational compounds: MK-2206 from Merck & Co., Inc. and AZD6244 (ARRY-886*) from AstraZeneca.

6 Jan 2010

UC San Diego bioengineering professor receives 2009 Presidential Science Prize

For Shu Chien - a pioneer in the growing field of bioengineering - understanding and learning the marvels of how the human body works has been the foundation of his decades-long quest to advance science and technology worldwide. The UC San Diego bioengineering professor's significant scientific endeavors have paved the way for recognition of his renowned work at the university's Jacobs School of Engineering and abroad.

6 Jan 2010

OncoMed Pharmaceuticals and Fluidigm announce new initiative to analyze tumor cell heterogeneity

OncoMed Pharmaceuticals, Inc. and Fluidigm Corporation today announced a new initiative to apply Fluidigm's unique microfluidic tools to the analysis of tumor cell heterogeneity, including cancer stem cells.

6 Jan 2010

Jumpstart and Portal Capital invest $500,000 in TheraVasc for PAD drug

JumpStart Inc., the Northeast Ohio venture development organization that accelerates the progress of high growth early-stage businesses, and Portal Capital, a Cleveland-based private equity firm investing in life science companies, each announce an investment commitment of $250,000 in TheraVasc Inc., for a total commitment of $500,000. The

6 Jan 2010

Opinions: U.S. medical emergency response; micronutrients; rotavirus vaccine; antibiotic development

"[D]espite the tireless efforts of public health and health-care workers, America's experience with H1N1 shows that the nation is not prepared to deal with a flu pandemic," former Democratic Senator Bob Graham and former Republican Senator Jim Talent write in Washington Post opinion piece that examines U.S. preparedness for medical emergencies. The writers chaired the Commission on the Prevention of Weapons of Mass Destruction Proliferation and Terrorism.

6 Jan 2010

Excaliard Pharmaceuticals initiates Phase 2 trials of EXC 001

Excaliard Pharmaceuticals, Inc. announced today the initiation of three proof of concept Phase 2 trials of EXC 001, an antisense medicine that reduces fibrosis, for the amelioration of skin scarring and other fibrotic disorders.

6 Jan 2010

EnVivo Pharmaceuticals announces initiation and dosing of patients in Phase 2b study of EVP-6124

EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase 2b study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with schizophrenia. EnVivo is conducting the multi-center, dose ranging, placebo controlled, three-month study in the U.S. and Europe.

6 Jan 2010

Health Canada approves Zyclara Cream for multiple actinic keratoses

Health Canada has approved Zyclara™ (imiquimod) Cream 3.75%, a topical prescription treatment for multiple actinic keratoses (AK) located on the face or balding scalp in adults. Actinic Keratosis is a common skin condition that can lead to squamous cell carcinoma, a form of non-melanoma skin cancer, if left untreated.

6 Jan 2010

IBI initiates Phase 2/3 pivotal clinical trial to assess the safety and efficacy of IBI-10090

Icon Bioscience, Inc., (IBI), a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic pharmaceuticals announced today that it has initiated its Phase 2/3 pivotal clinical trial to assess the safety and efficacy of IBI-10090 in patients undergoing cataract surgery.

6 Jan 2010

Cancer Research UK and CRT to undertake phase I clinical trial of DI-B4

CANCER RESEARCH UK and Cancer Research Technology (CRT), the charity's development and commercialisation arm, are to undertake a phase I clinical trial of an investigational monoclonal antibody1 drug from Merck KGaA, Darmstadt, Germany, called DI-B4 - it is announced today (Monday).

6 Jan 2010

USPTO issues a patent to CyDex Pharmaceuticals' Captisol technology

CyDex Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to CyDex entitled “Sulfoalkyl Ether Cyclodextrin Compositions.” This patent, along with other previously issued technology patents, will provide broad protection for CyDex’s Captisol® technology until 2029.

6 Jan 2010

Link Resources announces completion of share exchange transaction and private placement

Link Resources, Inc. announced today the completion of a share exchange transaction and concurrent US$12 million private placement pursuant to which it acquired the parent company of Yantai Bohai Pharmaceuticals Group Co., Ltd. (“Bohai”).

6 Jan 2010

BioMarin Pharmaceutical receives marketing approval for amifampridine phosphate

BioMarin Pharmaceutical Inc. announced today that the European Commission has granted marketing approval for 3,4-diaminopyridine (amifampridine phosphate), for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS).

6 Jan 2010

MonoSol Rx signs new licensing and development agreement with Strativa Pharmaceuticals

MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in proprietary pharmaceutical film products, announced today that it has entered into a new licensing and development agreement that grants the option to develop three new products with Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. ( PRX).

6 Jan 2010

Laureate Pharma, Selexis SA collaborate to provide streamlined access to complementary contract services

Laureate Pharma, Inc. a US based biopharmaceutical contract manufacturing organization and Selexis SA, a Swiss based contract developer of high performance production cell lines, jointly announced today their continued collaboration via a joint-marketing relationship. This expanded relationship provides streamlined access to a set of highly complementary contract services.

6 Jan 2010

DSMB recommends Quark Pharmaceuticals to continue clinical study of QPI-1002

Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today that the independent Data Safety Monitoring Board ("DSMB") recommended that QPI-1002 (I5NP) continue on to the next phase of clinical testing.

5 Jan 2010

Pharmaceuticals News and Research

Center for Technology and Aging announces grants to improve medication use in older adults

U.S. market for urological devices to reach over $5.4 billion in 2016

Historic low in drug spending growth coincides with cost-saving tools developed by PBMs

Study reveals majority of drug companies utilize in-house call centers

Patient enrolled in Phase I clinical study of two investigational compounds: MK-2206 and AZD6244

UC San Diego bioengineering professor receives 2009 Presidential Science Prize

OncoMed Pharmaceuticals and Fluidigm announce new initiative to analyze tumor cell heterogeneity

Jumpstart and Portal Capital invest $500,000 in TheraVasc for PAD drug

Opinions: U.S. medical emergency response; micronutrients; rotavirus vaccine; antibiotic development

Excaliard Pharmaceuticals initiates Phase 2 trials of EXC 001

EnVivo Pharmaceuticals announces initiation and dosing of patients in Phase 2b study of EVP-6124

Health Canada approves Zyclara Cream for multiple actinic keratoses

IBI initiates Phase 2/3 pivotal clinical trial to assess the safety and efficacy of IBI-10090

Cancer Research UK and CRT to undertake phase I clinical trial of DI-B4

USPTO issues a patent to CyDex Pharmaceuticals' Captisol technology

Link Resources announces completion of share exchange transaction and private placement

BioMarin Pharmaceutical receives marketing approval for amifampridine phosphate

MonoSol Rx signs new licensing and development agreement with Strativa Pharmaceuticals

Laureate Pharma, Selexis SA collaborate to provide streamlined access to complementary contract services

DSMB recommends Quark Pharmaceuticals to continue clinical study of QPI-1002

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence